• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

聚（亚烷基亚胺）树枝状大分子用有机金属 Mo 部分[Ru(η⁵-C₅H₅)(PPh₃)₂]⁺功能化作为有前途的抗耐药性癌细胞和人骨髓间充质干细胞的药物。

Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against -Resistant Cancer Cells and Human Mesenchymal Stem Cells.

机构信息

CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, Portugal.

Department of Chemistry, ScilifeLab, Umeå University, KBC-Building, Linnaeus väg 6, 90736 Umeå, Sweden.

出版信息

Molecules. 2018 Jun 17;23(6):1471. doi: 10.3390/molecules23061471.

DOI:10.3390/molecules23061471
PMID:29914219
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6100097/
Abstract

Here and for the first time, we show that the organometallic compound [Ru(η⁵-C₅H₅)(PPh₃)₂Cl] (RuCp) has potential to be used as a metallodrug in anticancer therapy, and further present a new approach for the cellular delivery of the [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ fragment via coordination on the periphery of low-generation poly(alkylidenimine) dendrimers through nitrile terminal groups. Importantly, both the RuCp and the dendrimers functionalized with [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ fragments present remarkable toxicity towards a wide set of cancer cells (Caco-2, MCF-7, CAL-72, and A2780 cells), including cisplatin-resistant human ovarian carcinoma cell lines (A2780R cells). Also, RuCp and the prepared metallodendrimers are active against human mesenchymal stem cells (hMSCs), which are often found in the tumor microenvironment where they seem to play a role in tumor progression and drug resistance.

摘要

本文首次表明，有机金属化合物[Ru(η⁵-C₅H₅)(PPh₃)₂Cl]（RuCp）具有作为抗癌治疗金属药物的潜力，并进一步提出了一种通过末端氰基基团在低代聚（亚烷基）树枝状大分子的外围配位将[Ru(η⁵-C₅H₅)(PPh₃)₂]⁺片段递送至细胞内的新方法。重要的是，既带有 RuCp 的又带有[Ru(η⁵-C₅H₅)(PPh₃)₂]⁺片段的树枝状大分子对广泛的癌细胞（Caco-2、MCF-7、CAL-72 和 A2780 细胞），包括顺铂耐药的人卵巢癌细胞系（A2780R 细胞）都表现出显著的毒性。此外，RuCp 和制备的金属树枝状大分子对人间充质干细胞（hMSCs）也有活性，hMSCs 通常存在于肿瘤微环境中，它们似乎在肿瘤进展和耐药性中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/238af937ca89/molecules-23-01471-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/3dd6e62be948/molecules-23-01471-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/c66ee35dd0f7/molecules-23-01471-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/6aa6cd0b022c/molecules-23-01471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/a0744b6205a3/molecules-23-01471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/238af937ca89/molecules-23-01471-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/3dd6e62be948/molecules-23-01471-g0A1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/c66ee35dd0f7/molecules-23-01471-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/6aa6cd0b022c/molecules-23-01471-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/a0744b6205a3/molecules-23-01471-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f38/6100097/238af937ca89/molecules-23-01471-g003.jpg

相似文献

1
Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs Against -Resistant Cancer Cells and Human Mesenchymal Stem Cells.聚（亚烷基亚胺）树枝状大分子用有机金属 Mo 部分[Ru(η⁵-C₅H₅)(PPh₃)₂]⁺功能化作为有前途的抗耐药性癌细胞和人骨髓间充质干细胞的药物。
Molecules. 2018 Jun 17;23(6):1471. doi: 10.3390/molecules23061471.
2
[RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺, a promising large spectrum antitumor agent: cytotoxic activity and interaction with human serum albumin.[RuII(η⁵-C₅H₅)(bipy)(PPh₃)]⁺，一种有前途的广谱抗肿瘤剂：细胞毒性活性及与人血清白蛋白的相互作用。
J Inorg Biochem. 2012 Dec;117:261-9. doi: 10.1016/j.jinorgbio.2012.06.016. Epub 2012 Jul 6.
3
Regulating the anticancer properties of organometallic dendrimers using pyridylferrocene entities: synthesis, cytotoxicity and DNA binding studies.使用吡啶基二茂铁实体调控有机金属树枝状大分子的抗癌特性：合成、细胞毒性及DNA结合研究
Dalton Trans. 2016 Jun 21;45(23):9529-39. doi: 10.1039/c6dt00849f. Epub 2016 May 19.
4
Effect of , Coordination and Ru Halide Bond in Enhancing Selective Toxicity of a Tyramine-Based Ru (-Cymene) Complex.芳基卤化物、配体配位和钌卤键协同作用增强基于酪胺的钌（-柠檬烯）配合物的选择性毒性。
Inorg Chem. 2020 May 4;59(9):6581-6594. doi: 10.1021/acs.inorgchem.0c00694. Epub 2020 Apr 15.
5
Cyclopentadienyl ruthenium(II) carbosilane metallodendrimers as a promising treatment against advanced prostate cancer.茂基金属碳硅烷树状大分子作为一种有前途的治疗晚期前列腺癌的方法。
Eur J Med Chem. 2020 Aug 1;199:112414. doi: 10.1016/j.ejmech.2020.112414. Epub 2020 May 8.
6
New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.新型细胞毒性水溶性双（2-苯基偶氮吡啶）钌（II）配合物
J Med Chem. 2003 Apr 24;46(9):1743-50. doi: 10.1021/jm021110e.
7
Organometallic dendrimers based on Ruthenium(II) N-heterocyclic carbenes and their implication as delivery systems of anticancer small interfering RNA.基于钌（II）氮杂环卡宾的有机金属树枝状大分子及其作为抗癌小分子干扰RNA递送系统的意义。
J Inorg Biochem. 2021 Oct;223:111540. doi: 10.1016/j.jinorgbio.2021.111540. Epub 2021 Jul 9.
8
Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.半胱氨酸巯基对 Ru(II)磺酰基乙二胺配合物的催化和抗癌活性的影响。
Dalton Trans. 2022 Mar 15;51(11):4447-4457. doi: 10.1039/d1dt03856g.
9
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.基于芳基钌（II）配合物的碳硅烷金属树状大分子的合成及抗癌活性。
Dalton Trans. 2016 Apr 28;45(16):7049-66. doi: 10.1039/c6dt00465b.
10
Cyclometalated Ru(II)-isoquinoline complexes overcome cisplatin resistance of A549/DDP cells by downregulation of Nrf2 via Akt/GSK-3β/Fyn pathway.环金属化 Ru(II)-异喹啉配合物通过 Akt/GSK-3β/Fyn 通路下调 Nrf2 来克服 A549/DDP 细胞的顺铂耐药性。
Bioorg Chem. 2022 Feb;119:105516. doi: 10.1016/j.bioorg.2021.105516. Epub 2021 Nov 25.

引用本文的文献

1
Target-Specific Delivery and Bioavailability of Pharmaceuticals via Janus and Dendrimer Particles.通过Janus和树枝状聚合物颗粒实现药物的靶向递送与生物利用度
Pharmaceutics. 2023 May 29;15(6):1614. doi: 10.3390/pharmaceutics15061614.
2
Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer.纳米载体与耐药肿瘤的相互作用：对抗癌症耐药性的新方法。
Cancer Drug Resist. 2021 Jun 19;4(2):264-297. doi: 10.20517/cdr.2020.81. eCollection 2021.
3
Recent advances in metallopolymer-based drug delivery systems.

本文引用的文献

1
Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex.阳离子脂质体作为一种高效的纳米载体，用于基于胆固醇的抗癌钌配合物的药物递送。
J Mater Chem B. 2015 Apr 21;3(15):3011-3023. doi: 10.1039/c4tb01807a. Epub 2015 Mar 5.
2
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.《国家癌症报告：第一部分：全国癌症统计数据》
Cancer. 2018 Jul 1;124(13):2785-2800. doi: 10.1002/cncr.31551. Epub 2018 May 22.
3
Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis.
基于金属聚合物的药物递送系统的最新进展。
RSC Adv. 2019 Nov 13;9(63):37009-37051. doi: 10.1039/c9ra06678k. eCollection 2019 Nov 11.
4
Amphiphilic Triazine-Phosphorus Metallodendrons Possessing Anti-Cancer Stem Cell Activity.具有抗癌干细胞活性的两亲性三嗪-磷金属树枝状大分子
Pharmaceutics. 2022 Feb 10;14(2):393. doi: 10.3390/pharmaceutics14020393.
5
Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.非侵入性鼻腔内给药途径直接进入大脑使用树枝状聚合物纳米平台：开发新的中枢神经系统药物的机会。
Eur J Med Chem. 2021 Jan 1;209:112905. doi: 10.1016/j.ejmech.2020.112905. Epub 2020 Oct 11.
6
Dendrimers: Amazing Platforms for Bioactive Molecule Delivery Systems.树枝状大分子：生物活性分子递送系统的惊人平台。
Materials (Basel). 2020 Jan 24;13(3):570. doi: 10.3390/ma13030570.
7
Synthesis, Characterisation and In Vitro Permeation, Dissolution and Cytotoxic Evaluation of Ruthenium(II)-Liganded Sulpiride and Amino Alcohol.合成、表征以及顺铂配位舒必利和氨基醇的体外渗透、溶解和细胞毒性评价。
Sci Rep. 2019 Mar 11;9(1):4146. doi: 10.1038/s41598-019-40538-1.
树状高分子的从基础研究到临床应用的转化：现实还是乌托邦？简要分析。
Adv Drug Deliv Rev. 2018 Nov-Dec;136-137:73-81. doi: 10.1016/j.addr.2017.11.007. Epub 2017 Nov 16.
4
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.抗癌钌（II）配合物的发展：从单分子化合物到纳米材料。
Chem Soc Rev. 2017 Oct 2;46(19):5771-5804. doi: 10.1039/c7cs00195a.
5
Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.铂、钯、金和钌配合物作为抗癌剂：当前临床应用、细胞毒性研究及未来展望。
Eur J Med Chem. 2017 Dec 15;142:8-31. doi: 10.1016/j.ejmech.2017.04.007. Epub 2017 Apr 18.
6
Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors.用于肿瘤靶向药物递送的钌配合物功能化纳米结构材料的最新进展。
Int J Nanomedicine. 2017 Apr 4;12:2749-2758. doi: 10.2147/IJN.S131304. eCollection 2017.
7
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action.基于钌的核-脂纳米聚集体在体外乳腺癌人类模型中的抗增殖作用：对其作用机制的深入了解。
Sci Rep. 2017 Mar 28;7:45236. doi: 10.1038/srep45236.
8
Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs).癌细胞在吞噬间充质干/基质细胞（MSC）后进入休眠状态。
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):E6447-E6456. doi: 10.1073/pnas.1612290113. Epub 2016 Oct 3.
9
Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.轴向位置的顺铂骨架和吲哚羧酸的基于 Pt(IV)前药诱导的氧化应激。
Sci Rep. 2016 Jul 11;6:29367. doi: 10.1038/srep29367.
10
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.基于芳基钌（II）配合物的碳硅烷金属树状大分子的合成及抗癌活性。
Dalton Trans. 2016 Apr 28;45(16):7049-66. doi: 10.1039/c6dt00465b.